Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Published:2022-03 Issue:3 Volume:7 Page:208-218
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Kaseb Ahmed Omar,Hasanov Elshad,Cao Hop Sanderson Tran,Xiao Lianchun,Vauthey Jean-Nicolas,Lee Sunyoung S,Yavuz Betul Gok,Mohamed Yehia I,Qayyum Aliya,Jindal Sonali,Duan Fei,Basu Sreyashi,Yadav Shalini S,Nicholas Courtney,Sun Jing Jing,Singh Raghav Kanwal Pratap,Rashid Asif,Carter Kristen,Chun Yun Shin,Tzeng Ching-Wei David,Sakamuri Divya,Xu Li,Sun Ryan,Cristini Vittorio,Beretta Laura,Yao James C,Wolff Robert A,Allison James Patrick,Sharma Padmanee

Funder

NIH

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference34 articles.

1. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang;Nat Rev Gastroenterol Hepatol,2019

2. Hepatocellular carcinoma: diagnosis and operative management;Chedid;Arq Bras Cir Dig,2017

3. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications;Portolani;Ann Surg,2006

4. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis;Tabrizian;Ann Surg,2015

5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial;Bruix;Lancet Oncol,2015

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for hepatocellular carcinoma;JHEP Reports;2024-10

2. Early identification of hepatocellular carcinoma patients at high-risk of recurrence using the ADV score: a multicenter retrospective study;World Journal of Surgical Oncology;2024-09-07

3. Natural killer (NK) cells-related gene signature reveals the immune environment heterogeneity in hepatocellular carcinoma based on single cell analysis;Discover Oncology;2024-09-04

4. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study;Journal of Hepatology;2024-09

5. Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era;Expert Review of Molecular Diagnostics;2024-08-28